Key result
Novel oxoisoindoline carboxamides show ~100-fold selectivity for NaV1.7 over NaV1.5 and reduce pain in rat models.
Novel oxoisoindoline carboxamides demonstrate potent, state-dependent NaV1.7 blockade with high selectivity over NaV1.5 and efficacy in rat pain models, suggesting potential as pain therapeutics.
May support NaV1.7-selective agents for pain; leaves open human translation and clinical validation.
The voltage-gated sodium channel Na(V)1.7 is believed to be a critical mediator of pain sensation based on clinical genetic studies and pharmacological results. Clinical utility of nonselective sodium channel blockers is limited due to serious adverse drug effects. Here, we present the optimization, structure-activity relationships, and in vitro and in vivo characterization of a novel series of Na(V)1.7 inhibitors based on the oxoisoindoline core. Extensive studies with focus on optimization of Na(V)1.7 potency, selectivity over Na(V)1.5, and metabolic stability properties produced several interesting oxoisoindoline carboxamides (16A, 26B, 28, 51, 60, and 62) that were further characterized. The oxoisoindoline carboxamides interacted with the local anesthetics binding site. In spite of this, several compounds showed functional selectivity versus Na(V)1.5 of more than 100-fold. This appeared to be a combination of subtype and state-dependent selectivity. Compound 28 showed concentration-dependent inhibition of nerve injury-induced ectopic in an ex vivo DRG preparation from SNL rats. Compounds 16A and 26B demonstrated concentration-dependent efficacy in preclinical behavioral pain models. The oxoisoindoline carboxamides series described here may be valuable for further investigations for pain therapeutics.
No takes yet. Share an insight, caveat, or question.
Macsári et al. (2012) studied Pain. Oxoisoindoline carboxamides was evaluated on NaV1.7 inhibition, selectivity over NaV1.5, and efficacy in preclinical behavioral pain models. Novel oxoisoindoline carboxamides demonstrated functional selectivity for NaV1.7 over NaV1.5 of more than 100-fold and showed concentration-dependent efficacy in preclinical rat pain models.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: